Evotec H1 2012: Building innovation on the back of profitable growth (Globenewswire) - Aug 8, 2012 - Evotec partnered in China with Conba especially for inflammation and endometriosis pain in April 2012 for EVT 401 a P2X7 antagonist
Licensing / partnership • Pain
|
|
EVT 401 partnered in China with Conba especially for inflammationIn April 2012, Evotec granted Zhejiang Jinhua Conba Bio-pharm. Co., Ltd. (Conba Pharmaceutical) a development and marketing license for its P2X7 antagonist, EVT 401, in China for human indications with exception of ophthalmological, chronic obstructive pulmonary disease (COPD) and endometriosis pain. Evotec obtained a small upfront payment and is eligible for development and commercial milestone payments in excess of €60 m, and tiered double-digit royalties on net sales.
(IR4)
|